Drug Trial Radar · NCT07579351
Corticosteroid Lumbar Epidural Analgesia for Radicular Pain 2
Last checked: Nov 19, 2026Latest source record: Sep 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
755
Planned (sponsor's estimate)
Start
Feb 2027
Primary completion
Nov 2028
Study completion Apr 2029
Sponsor
- Lead sponsor
- Semnur Pharmaceuticals, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Syngene; Cromos Pharma LLC
- First posted
- May 12, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a research study of SP-102, an experimental medication designed to relieve pain in patients with moderate to severe sciatica (pain in the lower back, hips, buttocks and legs). SP-102, placebo (a medication that looks like SP-102 but does not contain any active ingredient), or an active comparator (dexamethasone sodium phosphate) is given once by the participant's healthcare professional. If a participant meets qualifications, each participant will have the option of receiving one supplemental open-label injection of SP-102, greater than four weeks and up to twenty weeks after their first injection. The purpose of the study is to measure how well a single injection of the experimental medication, SP-102, relieves pain versus placebo. The study will also measure how well SP-102 relieves pain versus an active comparator medication (dexamethasone sodium phosphate). The study will also investigate the side effects of SP-102.
Conditions
- Lumbosacral Radicular Pain
Interventions
SP-102Drug
One Injection
PlaceboDrug
One injection
Dexamethasone Sodium Phosphate 10 MG/MLDrug
One injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Mean change from baseline to W4 in the mean NPRS average daily pain score.Time frame: Day 1 to week 4
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.